Back

FOXA1 preserves cell polarity and restrains lysosome biogenesis in non-small cell lung adenocarcinoma

Wang, X.; Zhang, B.; Sun, C.; Huang, M.; Huang, W.; Zhang, B.; Zhang, X.; Ren, X.; Luo, L.; Liang, H.; Zhou, Y.; Zhong, G.; Lin, S.; Tortorella, M. D.; Tan, T. Z.; Liang, W.; Thiery, J. P.; He, J.

2026-04-10 cancer biology
10.64898/2026.04.09.717383 bioRxiv
Show abstract

BackgroundThis study investigates the role of the pioneer transcription factor FOXA1 as a master gene in sustaining epithelial cell polarization in early-stage lung adenocarcinoma. The partial loss of FOXA1 is explored to determine if it will affect plasticity and progression of lung adenocarcinoma. The study also addresses the transcriptional circuitry that links polarity defects to lysosome homeostasis. MethodsA multiomics approach was used to define the status of the chromatin in epithelial and mesenchymal states of A549 adenocarcinoma cells obtained with a newly synthetized TGF-{beta} receptor inhibitor or TGF-{beta} respectively. The study leveraged ATAC-seq, RNA sequencing, Cut&Tag sequencing of FOXA1 and histone marks profiling. The functional impact of FOXA1 was examined by partial silencing in vitro and by heterozygous FOXA1 deletion in a KrasG12D mouse model. Three-dimensional organoid culture, high-resolution electron microscopy, spatial transcriptomics and multiplex immunohistochemistry assessed carcinoma cell polarity, proliferation, the tumor microenvironment and organelle content. Group differences were evaluated with two-tailed t tests or one-way analysis of variance. ResultsFOXA1 binding and expression were highest in cells harboring an epithelial phenotype. In mouse KrasG12D LUAD tumors FOXA1 marked polarized, CDH1-positive cells; heterozygous loss diminished CDH1, disrupted apical-basal architecture, lowered organoid-forming efficiency and remodeled the immune microenvironment. Spatial transcriptomics and ultrastructural analyses showed that FOXA1-deficient carcinoma cells accumulated lysosomes, down-regulated vesicle fusion genes of the SNARE family and activated the lysosomal CLEAR gene network. FOXA1 occupied enhancers of lysosome-associated genes and competed with the transcription factor TFE3, thereby suppressing transcription of cathepsin B and cathepsin C and restricting lysosome biogenesis. ConclusionsFOXA1 is a central regulator that preserves epithelial cell polarity and limits lysosome formation in lung adenocarcinoma. Targeting the FOXA1-TFE3-lysosome axis may affect tumor plasticity and provide new therapeutic opportunities.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 16%
10.8%
2
Molecular Oncology
50 papers in training set
Top 0.1%
7.0%
3
Cancers
200 papers in training set
Top 0.7%
6.6%
4
Scientific Reports
3102 papers in training set
Top 22%
5.0%
5
Frontiers in Oncology
95 papers in training set
Top 0.8%
4.3%
6
British Journal of Cancer
42 papers in training set
Top 0.5%
3.4%
7
Journal of Translational Medicine
46 papers in training set
Top 0.3%
3.2%
8
Frontiers in Immunology
586 papers in training set
Top 3%
3.0%
9
Molecular Cancer Research
42 papers in training set
Top 0.2%
2.4%
10
The Journal of Pathology
22 papers in training set
Top 0.1%
1.9%
11
EBioMedicine
39 papers in training set
Top 0.2%
1.9%
12
Cell Death Discovery
51 papers in training set
Top 0.5%
1.7%
50% of probability mass above
13
International Journal of Cancer
42 papers in training set
Top 0.6%
1.7%
14
Translational Oncology
18 papers in training set
Top 0.1%
1.7%
15
Cellular and Molecular Gastroenterology and Hepatology
41 papers in training set
Top 0.4%
1.5%
16
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
1.5%
17
Immunology
29 papers in training set
Top 0.5%
1.4%
18
F1000Research
79 papers in training set
Top 2%
1.4%
19
Biomedicines
66 papers in training set
Top 1%
1.3%
20
Computational and Structural Biotechnology Journal
216 papers in training set
Top 6%
1.3%
21
Oncotarget
15 papers in training set
Top 0.2%
1.1%
22
Journal of Clinical Medicine
91 papers in training set
Top 5%
1.0%
23
PLOS Computational Biology
1633 papers in training set
Top 21%
0.9%
24
Modern Pathology
21 papers in training set
Top 0.3%
0.9%
25
Clinical Epigenetics
53 papers in training set
Top 0.9%
0.8%
26
European Respiratory Journal
54 papers in training set
Top 2%
0.8%
27
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
28
Cancer Research Communications
46 papers in training set
Top 1%
0.8%
29
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.8%
30
Signal Transduction and Targeted Therapy
29 papers in training set
Top 1%
0.8%